Journal club: Overcoming endocrine resistance

摘要

Endocrine therapy is highly effective in estrogen receptor (ER) positive patients with breast cancer. However, in the metastatic setting a great number of patients do not respond to estrogen deprivation - either by blocking the ER or by lowering estrogen serum levels - due to primary or acquired resistance. Baselga et al. demonstrate that everolimus in addition to the aromatase inhibitor (AI) exemestane might be a way to overcome endocrine resistance as recently published in the NEJM. Robert Konigsberg discusses why and how this landmark study will change our daily clinical practice in hormone-receptor positive metastatic breast cancer.